Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services

Thursday, July 3, 2008 General News J E 4
BETHESDA, Md., July 2 Hanger Orthopedic Group,Inc. (NYSE: HGR) is pleased to announce that Standard & Poor's Rating Servicesrevised its outlook for Hanger Orthopedic Group, Inc. to "positive" from"stable." S&P also affirmed Hanger's corporate credit rating at "B." "Theoutlook revision reflects positive prospects for WalkAide and our expectationfor an improved financial risk profile," said Standard & Poor's credit analystRivka Gertzulin.

"We are pleased with the outlook change from S&P as it reflects our solidperformance over the last nine quarters and further recognition of our newbusiness prospects," remarked George McHenry, Hanger's Chief FinancialOfficer.

Hanger Orthopedic Group, Inc., headquartered in Bethesda, Maryland, is theworld's premier provider of orthotic and prosthetic patient care services.Hanger is the market leader in the United States, owning and operating 653patient care centers in 46 states and the District of Columbia, with over3,500 employees, including 1,067 practitioners (as of 3/31/08). Hanger isorganized into four units. The two key operating units are patient care whichconsists of nationwide orthotic and prosthetic practice centers anddistribution which consists of distribution centers managing the supply chainof orthotic and prosthetic componentry to Hanger and third party patient carecenters. The third is Linkia which is the first and leading provider networkmanagement company for the orthotics and prosthetics industry. The fourthunit, Innovative Neurotronics, introduces emerging neuromuscular technologiesdeveloped through independent research in a collaborative effort with industrysuppliers worldwide. For more information on Innovative Neurotronics, Inc. orthe WalkAide, visit For more information on Hanger, visit

SOURCE Hanger Orthopedic Group, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
USHIFU, LLC Completes Acquisition of Focus Surgery...
FDA Approves Abbott's XIENCE(TM) V Drug Eluting St...